Skip to main content
SpringerLink
Log in
Book cover

Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS pp 723–745Cite as

Toxic Nephropathy

  • Chapter

  • 321 Accesses

Abstract

The growing list of useful drugs and chemicals developed and released by the industry has been paralleled by an increased awareness of their potential for acute and chronic adverse renal reactions. Major advances in the understanding of how these drugs and environmental chemicals produce renal cell injury may be increasingly applicable to non-drug-related renal disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wedeen RP: Occupational renal disease. Am J Kidney Dis 3: 241–257, 1984.

    PubMed  CAS  Google Scholar 

  2. Houghton DC, Lee D, Gilbert DN, Bennett WM: Chronic gentamicin nephrotoxicity, continued tubular injury with preserved glomerular filtration function. Am J Pathol 123: 183–194, 1986.

    PubMed  CAS  Google Scholar 

  3. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH: Long-term effects of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41: 1274–1281, 1978.

    Article  PubMed  CAS  Google Scholar 

  4. Elzinga L, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol 4: 214–221, 1993.

    PubMed  CAS  Google Scholar 

  5. Gilbert DN, Houghton DC, Bennett WM, Plamp CE, Reger K, Porter GA: Reversibility of gentamicin nephrotoxicity in rats: recovery during continued drug administration. Proc Soc Exp Biol Med 160: 99–103, 1979.

    Article  PubMed  CAS  Google Scholar 

  6. Abramowsky CR, Swinehart GL: The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity. Hum Pathol 13: 934–939, 1982.

    Article  PubMed  CAS  Google Scholar 

  7. Rush GF, Smith JH, Newton JF, Hook JB: Chemically induced nephrotoxicity: role of metabolic activation. CRC Crit Rev Toxicol 13: 99–160, 1984.

    Article  CAS  Google Scholar 

  8. Clejan S, Bittman R: Rates of amphotericin B and filipin association with sterols. A study of changes in sterol structure and phospholipid composition of vesicles. J Biol Chem 260: 2884–2889, 1985.

    PubMed  CAS  Google Scholar 

  9. Jackson NM, Hsu C, Visscher GE, Venkatachalam MA, Humes HD: Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. J Pharmacol Exp Ther 242: 749–756, 1987.

    PubMed  CAS  Google Scholar 

  10. Sastrasinh M, Knauss TC, Weinberg JM, Humes HD: Identification of the aminoglycoside receptor of renal brush border membranes. J Pharmacol Exp Ther 222: 350–358, 1982.

    PubMed  CAS  Google Scholar 

  11. Weinberg JM, Hunt D, Humes HD: Distribution of gentamicin among subcellular fractions from rat renal cortex. Biochem Pharmacol 34: 1779–1787, 1985.

    Article  PubMed  CAS  Google Scholar 

  12. Mela-Riker LM, Widener LL, Houghton DC, Bennett WM: Renal mitochondrial integrity during continuous gentamicin treatment. Biochem Pharmacol 35: 979–984, 1986.

    Article  PubMed  CAS  Google Scholar 

  13. Bennett WM, Mela-Riker L, Houghton DC, Gilbert DN, Buss WC: Microsomal protein synthesis inhibition: an early manifestation of gentamicin nephrotoxicity. Am J Physiol 24: F265 - F269, 1988.

    Google Scholar 

  14. Gilbert D, Wood C, Kohlhepp S, Kohnen P, Houghton DC, Finkbeiner H, Lindsley J, Bennett WM: Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis 159: 945–953, 1989.

    Article  PubMed  CAS  Google Scholar 

  15. Tune BM, Fravert D: Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin. Kidney Int 18: 591–600, 1980.

    Article  PubMed  CAS  Google Scholar 

  16. Kotsonis FN, Klassen CD: Toxicity and distribution of cadmium administered to rats at sublethal doses. Toxicol Appl Pharmacol 41: 667–680, 1977.

    Article  PubMed  CAS  Google Scholar 

  17. Weinberg JM, Harding PG, Humes HG: Alterations in renal cortex cation homeostasis during mercuric chloride and gentamicin nephrotoxicity. Exp Mol Pathol 39: 43–60, 1983.

    Article  PubMed  CAS  Google Scholar 

  18. Mason RP: Free radical intermediates in the metabolism of toxic chemicals. In: Free Radicals in Biology, vol 5. Academic Press, New York, pp 161–170, 1982.

    Google Scholar 

  19. Zenser TV, Davis BB: Enzyme systems involved in the formation of reactive metabolites in the renal medulla: co-oxidation via prostaglandin H synthetase. Fund Appl Toxicol 4: 922–929, 1984.

    Article  CAS  Google Scholar 

  20. Mohandas J, Duggin GG, Horvath JS, Tiller DJ: Metabolic oxidation of acetaminophen mediated by cytochrome P-450 mixed function oxidase and prostaglandin endoperoxide synthetase in rabbit kidney. Toxicol Appl Pharmacol 61: 25 2259, 1981.

    Google Scholar 

  21. Kuo CH, Maita K, Sleight SD, Hook JB: Lipid peroxidation: a possible mechanism of cephaloridine-induced nephrotoxicity. Toxicol Appl Pharmacol 67: 78–88, 1983.

    Article  PubMed  CAS  Google Scholar 

  22. Fowler BA, Brooks RE: Effects of the herbicide paraquat on the ultrastructure of mouse kidney. Am J Pathol 63: 505–520, 1971.

    PubMed  CAS  Google Scholar 

  23. Humes HD, Weinberg JM: Alterations in renal tubular cell metabolism in acute renal failure. Miner Electrolyte Metab 9: 290–305, 1983.

    PubMed  CAS  Google Scholar 

  24. Just M, Erdmann G, Habermann E: The renal handling of polybasic drugs. I. Gentamicin and aprotinin in intact ani-

    Google Scholar 

  25. mals. Naunyn Schmiedebergs Arch Pharmacol 300:57–66, 1977.

    Google Scholar 

  26. De Broe ME, Paulus GJ, Verpooten GA, Roels F, Buyssens N, Wedeen R, Van Hoff F, Tulkens PM: Early effects of gentamicin, tobramycin and amikacin on the human kidney. Kidney Int 25: 643–652, 1984.

    Article  PubMed  Google Scholar 

  27. Lullmann H, Lullmann-Rauch R, Wassermann O: Drug-induced phospholipidosis. CRC Crit Rev Toxicol 4: 185–218, 1975.

    PubMed  CAS  Google Scholar 

  28. Kaloyanides GJ: Aminoglycoside-induced functional and biochemical defects in the renal cortex. Fund Appl Toxicol 4: 930–943, 1984.

    Article  CAS  Google Scholar 

  29. Kleinknicht D, Landais P, Goldfarb B: Drug associated acute renal failure: a prospective multicenter report. Proc EDTAERA 22: 1002, 1988.

    Google Scholar 

  30. Humes HD, Weinberg JM, Knauss TC: Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 2: 5–29, 1982.

    PubMed  CAS  Google Scholar 

  31. Whelton A: Therapeutic initiatives for the avoidance of aminoglycoside toxicity. J Clin Pharmacol 25: 67–81, 1985.

    Article  PubMed  CAS  Google Scholar 

  32. Burdmann EA, Andoh TF, Lindsley J, Russell J, Bennett WM, Porter GA: Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Ren Fail 16: 161–168, 1994.

    Article  PubMed  CAS  Google Scholar 

  33. Houghton DC, Hartnett MN, Campbell-Boswell M, Porter GA, Bennett WM: A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am J Pathol 82: 589–612, 1976.

    PubMed  CAS  Google Scholar 

  34. Bennett WM, Gilbert DN, Houghton D, Porter GA: Gentamicin nephrotoxicity in man: morphologic and pharmacologic features. West J Med 126: 65–68, 1977.

    Google Scholar 

  35. Bennett WM: Mechanisms of aminoglycoside nephrotoxicity. Clin Exp Pharmacol Physiol 16: 1–6, 1989.

    Article  PubMed  CAS  Google Scholar 

  36. Hruban Z, Slessers A, Hopkins E: Drug-induced and naturally occurring myeloid bodies. Lab Invest 27: 62–70, 1972.

    PubMed  CAS  Google Scholar 

  37. Mandal A, Bennett WM: Transmission electron microscopy of urinary sediment in the assessment of aminoglycoside nephrotoxicity in the rat. Nephron 49: 45–53, 1988.

    Article  Google Scholar 

  38. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA: The influence of dosage regime on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 140: 576–580, 1979.

    Article  PubMed  CAS  Google Scholar 

  39. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, Groden DL, Jacobs MR, DiScenna AO, Cash HA, Klinger JD: Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramicin. J Infect Dis 147: 918–932, 1983.

    Article  PubMed  CAS  Google Scholar 

  40. Gilbert DN: Once daily aminoglycoside dosing. Antimicrob Agents Chemother 36: 121–124, 1992.

    Article  Google Scholar 

  41. Swan SK, Gilbert DN, Kohlhepp SJ, Kohnen PW, Bennett WM: Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity. Antimicrob Agents Chemother 37: 347–348, 1993.

    Article  PubMed  CAS  Google Scholar 

  42. English J, Gilbert DN, Kohlhepp SJ, Kohnen PW, Mayor G, Houghton DC, Bennett WM: Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother 27: 897–902, 1985.

    Article  PubMed  CAS  Google Scholar 

  43. Appel GB, Kunis CL: Acute tubulointerstitial nephritis. In: RS Cottan, ed, Tubulo-interstitial Nephropathies. Churchill-Livingstone, New York, pp 151–160, 1982.

    Google Scholar 

  44. Fillastre JP, Kleinknecht D: Acute renal failure associated with cephalosporin therapy. Am Heart J 89: 809–810, 1975.

    CAS  Google Scholar 

  45. Glauser MP, Neftel KA: Toxicology and pharmacologic considerations in the choice of empiric parenteral antibiotics. Am J Med 801: 64–69, 1986.

    Google Scholar 

  46. Tune BM: Relationship between the transport and toxicity of cephalosporins in the kidney. J Infect Dis 132: 189–194, 1975.

    Article  PubMed  CAS  Google Scholar 

  47. Tune BM: Nephrotoxicity of cephalosporin antibiotics: mechanisms and modifying factors. In: GA Porter, ed, Nephrotoxic Mechanisms of Drugs and Environmental Toxins. Plenum Medical, New York, pp 151–164, 1982.

    Chapter  Google Scholar 

  48. Abraham EP: Cephalosporins, 1945–1986. Drugs 34: 1–14, 1987.

    Article  PubMed  CAS  Google Scholar 

  49. Birnbaum J, Kahan FA, Kropp H, MacDonald JS: Carbopenems, a new class of Beta-lactose antibiotics. Am J Med 78: 3–21, 1985.

    Article  PubMed  CAS  Google Scholar 

  50. Appel GB, Gwen DB, Levine L, Cooper GL: Vancomycin and the kidney. Am J Kidney Dis 8: 75–80, 1986.

    PubMed  CAS  Google Scholar 

  51. Edwards OM, Huskisson EC, Taylor R: Azotemia aggravated by tetracycline. Br Med J 1: 26–27, 1970.

    Article  PubMed  CAS  Google Scholar 

  52. Forrest JN, Cox M, Hong C, Morrison G, Bia M, Singer I: Superiority of demeclocycline over lithium in the treatment of chronic pyrelume of inappropriate secretion of antidiuretic hormone. N Engl J Med 298: 173–177, 1978.

    Article  PubMed  Google Scholar 

  53. Butler WT, Bennett JE, Ailing DW: Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 61: 175–178, 1964.

    Article  PubMed  CAS  Google Scholar 

  54. Douglas JB, Healy JK: Nephrotoxicity effects of amphotericin B, including renal tubular acidosis. Am J Med 46: 154162, 1969.

    Google Scholar 

  55. Gerkens JF, Heidemann HT, Jaeleson EK, Branch AA: Effect of aminophylline on amphotericin B nephrotoxicity in the dog. J Pharmacol Exp Ther 224: 609–613, 1983.

    PubMed  CAS  Google Scholar 

  56. Branch RA: Prevention of amphotericin B-induced renal impairment: a review of the use of sodium supplementation. Arch Intern Med 148: 2389–2394, 1988.

    Article  PubMed  CAS  Google Scholar 

  57. Sawyer MH, Webb DE, Balow JE, Straus SE: Acyclovirinduced renal failure. Am J Med 84: 1067–1071, 1988.

    Article  PubMed  CAS  Google Scholar 

  58. Anderson R, Boedicker M, Ma M, Goldstein EJ: Adverse reactions associated with pentamidine isothionate in AIDS patients: recommendations for monitoring therapy. Drug Intell Clin Pharmacol 20: 862–868, 1986.

    Google Scholar 

  59. Bennett WM, Porter GA: Overview of clinical nephrotoxicity. In: JB Hook, RS Goldstein, eds, Toxicology of the Kidney. Raven Press, New York, pp 61–97, 1993.

    Google Scholar 

  60. Swan SK, Bennett WM: Nephrotoxic acute renal failure. In: M Lazarus, B Brenner, eds, Acute Renal Failure. Churchill Livingstone, New York, pp 357–392, 1993.

    Google Scholar 

  61. Bennett WM, Elzinga LW, Porter GA: Tubulointerstitial disease and toxic nephropathy. In: B Brenner, F Rector, eds, The Kidney, 4th ed. WB Saunders, Philadelphia, pp 14301496, 1991.

    Google Scholar 

  62. Berkseth RO, Kjellstrand CM: Radiologic contrast-induced nephropathy. Med Clin North Am 68: 351–370, 1984.

    PubMed  CAS  Google Scholar 

  63. D’Elia JA, Gleason RE, Alday M, Malarick C, Godley K, Warram J, Kaldany A, Weinranch A: Nephrotoxicity from angiographic contrast media. Am J Med 72: 719–725, 1982.

    Article  PubMed  Google Scholar 

  64. Cochran ST, Wong WS, Roe DJ: Predicting angiographyinduced acute renal function impairment: clinical risk model. AJR 141: 1027–1033, 1983.

    Article  PubMed  CAS  Google Scholar 

  65. Kleinknecht D, Landais P, Goldfarb B: Pathophysiology and clinical aspects of drug-induced tubular necrosis in man. Contr Nephrol 55: 145–158, 1987.

    CAS  Google Scholar 

  66. Katzberg RW, Schulman G, Meggs LG, Caldicott WJ, Damiano MM, Hollenberg NK: Mechanism of renal response to contrast medium in dogs. Invest Radiol 18: 74–80, 1983.

    Article  PubMed  CAS  Google Scholar 

  67. Katzberg RW, Pabico RC, Morris TW, Hayakawa K, McKenna BA, Panner BJ, Ventura JA, Fischer HW: Effects of contrast media on renal function and subcellular morphology in the dog. Invest Radio! 21: 64–70, 1986.

    Article  CAS  Google Scholar 

  68. Rudrick MR, Berns JS, Cohen RM: Contrast media-associated nephrotoxicity. Curr Opin Nephrol Hypertens 5: 127–133, 1996.

    Article  Google Scholar 

  69. Schwab SJ, Hlatley MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, Bashore TM: Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 320: 149–153, 1989.

    Article  PubMed  CAS  Google Scholar 

  70. Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65: 307–314, 1978.

    Article  PubMed  CAS  Google Scholar 

  71. Harmon WE, Cohen JH, Schneeberger EE, Grupe WE: Chronic renal failure in children treated wtih methyl CCNU. N Engl J Med 300:1200–1203, 1979. Nichols WC, Moertel CG: Nephrotoxicity of methyl CCNU. N Engl J Med 301: 1181, 1979.

    Google Scholar 

  72. Fox RM: Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol Suppl 5: 43–45, 1979.

    PubMed  CAS  Google Scholar 

  73. Jacobs SA, Stoller RG, Chabner BA, Johns DG: Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 57: 534–538, 1976.

    Article  PubMed  CAS  Google Scholar 

  74. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J: Cisplatin nephrotoxicity. Am J Kidney Dis 8: 356–367, 1986.

    PubMed  CAS  Google Scholar 

  75. Canetta R, Rozencwerg M, Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rep (Suppl A): 125–136, 1985.

    Google Scholar 

  76. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees JP, Baker J, Ford HT: Carboplatin: a very active new cisplatin analog in treatment of small cell lung cancer. Cancer Treat Rep 69: 43–46, 1985.

    PubMed  CAS  Google Scholar 

  77. Schilsky RL, Anderson T: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90: 929–931, 1979.

    Article  PubMed  CAS  Google Scholar 

  78. Ellis ME, Weiss RB, Kuperminc M: Nephrotoxicity of iomustine: a case report and literature review. Cancer Chemother Pharmacol 15: 174–175, 1985.

    Article  PubMed  CAS  Google Scholar 

  79. Schacht RG, Feiner HD, Gallo GR, Lieberman A, Baldwin DS: Nephrotoxicity of nitrosoureas. Cancer 48: 1328–1334, 1981.

    Article  PubMed  CAS  Google Scholar 

  80. Schein PS, O’Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, Wiernik PH, Ziegler JL, DeVita VT: Clinical antitumor activity and toxicity of streptozotocin (NSC 85998). Cancer 34: 993–1000, 1974.

    Article  PubMed  CAS  Google Scholar 

  81. Bertino JR, Condos S, Horvath C, Kalghatgi K, Pedersen IT: Immobilized carboxypeptidase G, in methotrexate removal. Cancer Res 38: 1936–1941, 1978.

    PubMed  CAS  Google Scholar 

  82. Kennedy BJ: Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 49: 494–503, 1970.

    Article  PubMed  CAS  Google Scholar 

  83. Giroux L, Bettez P, Giroux L: Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases. Am J Kidney Dis 6: 2839, 1985.

    Google Scholar 

  84. Weening JJ, Rennke HG: Glomerular permeability and polyanion in adriamycin nephrosis in the rat. Kidney Int 24: 152–159, 1983.

    Article  PubMed  CAS  Google Scholar 

  85. Bennett WM: Clinical aspects of cyclosporine in nephrotoxicity. In: M Hatano, et al., eds, Nephrology. Springer-Verlag, Tokyo, pp 564–575, 1991.

    Google Scholar 

  86. First MR, Schroeder TJ, Weiskittel P, Moscini L, Benigni A, Amuchastegui CS, Gasparini F, Remuzzi G: Concomitant administration of cyclosporine and ketoconazole in renal transplant recipients. Lancet 2: 1198–1201, 1989.

    Article  PubMed  CAS  Google Scholar 

  87. Greenberg A, Egel JW, Thompson ME, Hardesty RL, Griffith BP, Bahnson HT, Bernstein RL, Hastillo A, Hess Ml, Puschett JB: Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant patients. Am J Kidney Dis 9: 12–22, 1987.

    PubMed  CAS  Google Scholar 

  88. Conte G, Dal Canton A, Sabbatini M, et al.: Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects. Kidney Int 36: 1086–1092, 1989.

    Article  PubMed  CAS  Google Scholar 

  89. Perico N, Ruggenenti P, Gaspari P, Moscini L, Benigni A, Amuchastequi CS, Gasparini F, Remuzzi G: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54: 56–60, 1992.

    Article  PubMed  CAS  Google Scholar 

  90. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P: Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 2: 477–479, 1986.

    Article  PubMed  CAS  Google Scholar 

  91. Neild GH, Taube DH, Hartley RB, Bignardi L, Cameron JS, Williams DG, Ogg CS, Rudge CJ: Morphological differentiation between rejection and cyclosporine nephrotoxicity in renal allografts. J Clin Pathol 39: 152–159, 1986.

    Article  PubMed  CAS  Google Scholar 

  92. Myers BD: Cyclosporine nephrotoxicty. Kidney Int 30: 964974, 1986.

    Google Scholar 

  93. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699–705, 1984.

    Article  PubMed  CAS  Google Scholar 

  94. Wheatley HC, Daltzman M, Williams JW, et al.: Long-term effects of cyclosporine on renal function in liver transplant recipients. Transplantation 43: 641–647, 1987.

    Article  PubMed  CAS  Google Scholar 

  95. Palestine AG, Austin HA, Balow JE, et al.: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314: 1293–1298, 1986.

    Article  PubMed  CAS  Google Scholar 

  96. Myers BD, Sibley R, Newton L, et al.: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33: 590–600, 1988.

    Article  PubMed  CAS  Google Scholar 

  97. Mihatsch MJ, Thiel G, Basler V, Ruffel B, Landmann J, Von Overbeck J, Zollinger HV: Morphologic patterns in cyclosporine-treated renal transplant recipients. Transplant Proc 17 (Suppl 1): 101–116, 1985.

    PubMed  CAS  Google Scholar 

  98. Shulman H, Striker G, Deeg HJ, Kennedy M, Storb R, Thomas ED: Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 305: 1392–1395, 1981.

    Article  PubMed  CAS  Google Scholar 

  99. Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD: De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98: 54–62, 1985.

    PubMed  Google Scholar 

  100. Grace AA, Barradas MA, Midhailidis DP, Jeremy JY, Moorhead JF, Sueny P, Dandona P: Cyclosporine A enhances platelet aggregation. Kidney Int 32: 889–895, 1987.

    Article  PubMed  CAS  Google Scholar 

  101. Bennett WM, Porter GA: Cyclosporine-associated hypertension. Am J Med 85: 131–133, 1988.

    Article  PubMed  CAS  Google Scholar 

  102. Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J: Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system. Am J Cardiol 56: 927–931, 1985.

    Article  PubMed  CAS  Google Scholar 

  103. Curtis JJ, Luke RG, Jones P, Diethelm AG: Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 85: 134–138, 1988.

    Article  PubMed  CAS  Google Scholar 

  104. Xue H, Bukoski R, McCarron DA, Bennett WM: Cyclosporin A induces contraction in isolated rat aorta. Transplantation 43: 715–715, 1987.

    Article  PubMed  CAS  Google Scholar 

  105. Whitworth JA, Mills EH, Coghland JP, McDougall JG, Nelson MA, Spence CD, Tresham JJ, Scoggins BA: The hemodynamic effects of cyclosporine in sheep. J Exp Pharmacol Physiol 14: 573–580, 1987.

    Article  CAS  Google Scholar 

  106. Textor SC, Fornan SJ, Borer W, Carlson J: De novo accelerated hypertension during sequential cyclosporine and prednisone therapy in normotensive bone marrow transplant recipients. Trans Proc 20 (Suppl 3): 480–486, 1988.

    CAS  Google Scholar 

  107. Hiestand PC, Graber M, Hurtenbach U, Herrmann P, Commisuli S, Richardson BP, Eberle MK, Donatsch P, Ryffel B, Borel JF: New cyclosporine derivative SD2 IMM125: in vitro and in vivo pharmacologic effects and toxicologic evaluation. Transplant Proc 25: 691–692, 1993.

    PubMed  CAS  Google Scholar 

  108. Burdmann EA, Andoh TF, Rosen S, Lindsley J, Munar M, Elzinga LW, Bennett WM: Experimental nephrotoxicity, hepatoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int 45: 684–691, 1994.

    Article  PubMed  CAS  Google Scholar 

  109. Henry M, Elkhammas EA, Tesi RJ, Ferguson RM: A randomized prospective trial of 0G-37–325 versus cyclosporine in cadaveric renal transplantation. Am Soc Transplant Phys 12: 125, 1993.

    Google Scholar 

  110. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM: Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 57: 483–489, 1994.

    PubMed  CAS  Google Scholar 

  111. Pirsch J, the U.S. Multi-center FK506 Liver Study Group: Renal and metabolic effects of liver transplantation: comparison of FK506 to CyA with respect to GFR, hypertension, hyperglycemia and hyperkalemia. Am Soc Transplant Phys 12: 153, 1993.

    Google Scholar 

  112. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 17: 60–68, 1993.

    Article  PubMed  CAS  Google Scholar 

  113. DiJoseph JF, Sharma RN, Chang JY: The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 52: 507–513, 1992.

    Article  Google Scholar 

  114. Henrich W: Nephrotoxicity of nonsteroidal antiinflammatory agents. In: R Schrier, C Gottschalk, eds, Diseases of the Kidney. Little, Brown, Boston, pp 1203–1218, 1992.

    Google Scholar 

  115. Miller ISM, Bednar MM, McGiff JC: Renal metabolism of sulindac: functional implications. J Pharmacol Exp Ther 281: 449–456, 1984.

    Google Scholar 

  116. Klassen DK, Stout RL, Spilman PS, Whelton A: Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. J Clin Pharmacol 29: 1037–1042, 1986.

    Article  Google Scholar 

  117. Ciabattoni G, Cinotti GA, Pierucci A, Simonetti BM, Manzi M, Pagliese F, Barsotti P, Pecci G, Taggi F, Patrono C: Effects of sulindac and ibuprofen in patients with chronic glomerular disease. N Engl J Med 310: 279–283, 1984.

    Article  PubMed  CAS  Google Scholar 

  118. Quintero E, Gines P, Arroyo V, Rimola A, Camps J, Gaya J, Guerara A, Rodamilans M, Rodes J: Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 42: 298–303, 1986.

    Article  PubMed  CAS  Google Scholar 

  119. Shah GM, Muhalwas KK, Winer RL: Renal papillary necrosis due to ibuprofen. Arthritis Rheum 24: 1208–1210, 1981.

    Article  PubMed  CAS  Google Scholar 

  120. Adams DH, Michael J, Bacon PA, Howie AJ, McConkey B, Adu D: Non-steroidal anti-inflammatory drugs and renal failure. Lancet 1: 57–60, 1986.

    Article  PubMed  CAS  Google Scholar 

  121. Williams RC: Changes in lymphocyte cell surface markers in human disease states. Clin Immunol Rev 1: 409–469, 1981 1982.

    Google Scholar 

  122. Henann NE, Morales JR: Suprofen-induced acute renal failure. Drug Intel(Clin Pharmacol 20: 860–862, 1986.

    CAS  Google Scholar 

  123. Sipila R, Skrifvars BO, Tornroth T: Reversible non-oliguric impairment of renal function during azapropazone treatment. Scand J Rheumatol 15: 23–26, 1986.

    Article  PubMed  CAS  Google Scholar 

  124. Schneider PD: Nonsteroidal anti-inflammatory drugs and acute cortical necrosis. Ann Intern Med 105: 303–304, 1986.

    Article  PubMed  CAS  Google Scholar 

  125. Dubach UC: Analgetika-Nephropathie in der Schweiz. Z Urol Nephrol 82: 143–144, 1989.

    Google Scholar 

  126. Elseviers MM, DeBroe, ME: Is analgesic nephropathy still a problem in Belgium? Nephrol Dial Transplant 2: 143–149, 1988.

    Google Scholar 

  127. Pommer W, Glaeske G, Molzahn M: The analgesic problem in the Federal Republic of Germany: analgesic consumption, 744 Therapy of Renal Diseases & Related Disorders frequency of analgesic nephropathy and regional differences. Clin Nephrol 26: 273–278, 1986.

    PubMed  CAS  Google Scholar 

  128. U.S. Renal Data System: USRDS 1993 Annual Data Report. NIDDK, Bethesda, MD, March 1993.

    Google Scholar 

  129. IPCS/CEC Environmental Health Criteria 119. Principles and Methods for the Assessment of Nephrotoxicity Associated with Exposure to Chemicals. Geneva: World Health Organization, 1991.

    Google Scholar 

  130. Prescott LF: Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs 23: 75–149, 1982.

    Article  PubMed  CAS  Google Scholar 

  131. Elseviers MM, DeBroe MM: Epidemiology of analgesic nephropathy. J Nephrol 5: 94–98, 1992.

    Google Scholar 

  132. Murray TG, Stolley PD, Anthony JC, Schinnar R, HeplerSmith E, Jeffreys JL: Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 143: 1687–1693, 1983.

    Article  PubMed  CAS  Google Scholar 

  133. McCredie M, Stewart JH, Nlahony JF: Is phenacetin responsible for analgesic nephropathy in New South Wales? Clin Nephrol 17: 134–140, 1982.

    PubMed  CAS  Google Scholar 

  134. Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, Blythe WB, Burgess WP: Analgesic use and chronic renal disease. N Engl J Med 320: 1238–1243, 1989.

    Article  PubMed  CAS  Google Scholar 

  135. Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, Borner K, Molzahn M: Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 9: 403412, 1989.

    Google Scholar 

  136. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PH: End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 30: 717–723, 1990.

    Article  PubMed  CAS  Google Scholar 

  137. Dubach UC, Rosner B, Pfister E: Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968–1979). N Engl J Med 308: 357–362, 1983.

    Article  PubMed  CAS  Google Scholar 

  138. Dubach UC, Rosner B, Sturmer T: An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968–1987). N Engl J Med 324: 155–160, 1991.

    Article  PubMed  CAS  Google Scholar 

  139. Elseviers MM, DeBroe ME: Wurde das Problem der Analgetika-Nephropathie durch die Entfernung des Penacetins aus analgetischen Mischpraparaten gelost? Mitt Klin Nephrol 16: 187–193, 1987.

    Google Scholar 

  140. Kincaid-Smith P: Analgesic nephropathy in Australia. Contrib Nephrol 16: 57–64, 1979.

    PubMed  CAS  Google Scholar 

  141. Nanra RS, Disney APS, Excell L: Changes in pattern of renal failure in analgesic nephropathy following restriction of analgesic sales in Australia. Nephrol Dial Transplant 7: 708–709, 1992.

    Google Scholar 

  142. Disney APS, Scheil AGR, Roy P: Fourteenth Report of the Australia and New Zealand Dialysis and Transplant Registry (ANZ DATA). October 1991.

    Google Scholar 

  143. Bengtsson U: Analgetika-Nephropathis–Langfristige Erfahrungen aus Schweden. Z Urol Nephrol 82: 121–125, 1989.

    Google Scholar 

  144. Wessling A: Over-the-counter sales of drugs in Sweden 19761983. Eur J Clin Pharmacol 33: 1–6, 1987.

    Article  PubMed  CAS  Google Scholar 

  145. DeBroe ME, Elseviers MM: Analgesic nephropathy-still a problem? Nephron 64: 505–513, 1993.

    Article  CAS  Google Scholar 

  146. Elseviers MM, Bosteels V, Cambier P, De Paepe M, Godon JP, Lins R, Lornoy W, Matthys E, Moeremans C, Roose R, Theelen B, Van Caesbroeck D, Verbanck J, De Broe ME: Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol Dial Transplant 7: 479–486, 1992.

    PubMed  CAS  Google Scholar 

  147. Buckalew VM, Schey HM: Analgesic nephropathy: a significant cause of morbidity in the United States. Am J Kidney Dis 7: 164–168, 1986.

    PubMed  Google Scholar 

  148. Wing AJ, Brunner FP, Geerlings W: Contribution of toxic nephropathies to end-stage renal failure in Europe: a report from the EDTA-ERA Registry. Toxicol Lett 46: 281–292, 1989.

    Article  PubMed  CAS  Google Scholar 

  149. Seedat YK, Naicker S, Rawat R, Parsoo I: Racial differences in the causes of end-stage renal failure in Natal. S Afr Med J 65: 956–958, 1984.

    PubMed  CAS  Google Scholar 

  150. Segasothy M, Suleiman AB, Puvaneswary M, Rohana A: Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 50: 50–54, 1988.

    Article  PubMed  CAS  Google Scholar 

  151. McAnally JF, Winchester JF, Schreiner GE: Analgesic nephropathy. An uncommon cause of end-stage renal disease. Arch Intern Med 143: 1897–1899, 1983.

    Article  PubMed  CAS  Google Scholar 

  152. Gonwa TA, Hamilton RW, Buckalew VM: Chronic renal failure and end-stage renal disease in northwestern North Carolina. Importance of analgesic associated nephropathy. Arch Intern Med 141: 462–465, 1981.

    Article  PubMed  CAS  Google Scholar 

  153. Wedeen RP: Poison in the Pot. Southern Illinois Press, Carbondale, IL, 1985.

    Google Scholar 

  154. Lancereaux E: Nephrite et arthrite saturnines: coincidence de ces affections: Parallele avec la nephrite el l’arthrite goutteuses. Arch Gen Med Par 6: 641–644, 1881.

    Google Scholar 

  155. Bennett WM: Lead nephropathy. Kidney Int 28: 212–220, 1985.

    Article  PubMed  CAS  Google Scholar 

  156. Klein M, Namer R, Harpur E, Corbin R: Earthenware containers as a source of fatal lead poisoning. N Engl J Med 283: 669–672, 1970.

    Article  PubMed  CAS  Google Scholar 

  157. Wedeen RP, Mallik DK, Batumen V: Detection and treatment of occupational lead nephropathy. Arch Intern Med 139: 53–57, 1979.

    Article  PubMed  CAS  Google Scholar 

  158. Batuman V, Landy E, Maesaka JK, Wedeen RP: Contribution of lead to hypertension with renal impairment. N Engl J Med 309: 17–21, 1983.

    Article  PubMed  CAS  Google Scholar 

  159. Batuman V, Maesaka JK, Haddad B, Tepper E, Landy E, Wedeen RP: The role of lead in gout nephropathy. N Engl J Med 304: 520–523, 1981.

    Article  PubMed  CAS  Google Scholar 

  160. Mistry P, Lucier GW, Fowler BA: High-affinity lead-binding proteins in rat kidney cytosol mediate cell-free nuclear translocation of lead. J Pharmacol Exp Ther 232: 462–469, 1985.

    PubMed  CAS  Google Scholar 

  161. Chisolm JJ, Baltrop D: Recognition and management of children with increased lead absorption. Arch Dis Child 54: 249262, 1979.

    Google Scholar 

  162. Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, Thomas BJ, Thomas BW: Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int 26: 319–323, 1984.

    Article  PubMed  CAS  Google Scholar 

  163. Harlan WR, Landis JR, Schmouder RL: Blood lead and blood pressure relationship in the adolescent and adult U.S. population. JAMA 253: 530–534, 1985.

    Article  PubMed  CAS  Google Scholar 

  164. McAllister RG, Michelakis AM, Sanstead HH: Plasma renin activity in chronic plumbism. Arch Intern Med 127: 919–923, 1971.

    Article  PubMed  Google Scholar 

  165. Suzuki CA, Cherian MG: Renal toxicity of cadmiummetallothionein and enzymuria in rats. J Pharmacol Exp Ther 240: 314–314, 1987.

    PubMed  CAS  Google Scholar 

  166. Roels HA, Lauwerys R, Buchet JP, Bernard A, Chettle DR, Harvey TC, Al-Haddad IK: In vivo measurement of liver and kidney cadmium in workers exposed to this metal: its significance with respect to cadmium in blood and urine. Environ Res 26: 217–240, 1981.

    Article  PubMed  CAS  Google Scholar 

  167. Friberg L: Cadmium and the kidney. Environ Health Perspect 54: 1–11, 1984.

    Article  PubMed  CAS  Google Scholar 

  168. Nogawa K: Biologic indicators of cadmium nephrotoxicity in persons with low-level cadmium exposure. Environ Health Perspect 54: 163–169, 1984.

    Article  PubMed  CAS  Google Scholar 

  169. Lauwerys R, DeWals P: Environmental pollution by cadmium and mortality from renal diseases. Lancet 1: 383, 1981.

    Article  CAS  Google Scholar 

  170. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ: Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenoses or renal artery stenosis in a solitary kidney. N Engl J Med 308: 373376, 1983.

    Google Scholar 

  171. Coulie P, de Plaen JF, van Ypersele de Strihou C: Captoprilinduced acute reversible renal failure. Nephron 35: 108–111, 1983.

    Article  PubMed  CAS  Google Scholar 

  172. Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP: Inhibition of angiotensin-converting enzyme in renal transplant recipients with hypertension. N Engl J Med 308: 377–381, 1983.

    Article  PubMed  CAS  Google Scholar 

  173. Brown AR, Williams PF: Irreversible renal transpant failure after enalapril therapy. Br Med J 292: 732, 1986.

    Article  Google Scholar 

  174. Scanu P, de Ligny H, Ryckelynck JP: Reversible acute renal insufficiency with combination of enalapril and diuretics in a patient with a single renal artery stenosis. Nephron 45: 32 1322, 1987.

    Google Scholar 

  175. Cunningham EE, Zielezny MA, Venuta RC: Heroin-associated nephropathy—a nationwide problem. JAMA 250: 2935–2936, 1983.

    Article  PubMed  CAS  Google Scholar 

  176. Sreepada TK, Nicastri AD, Friedman EA: Renal consequences of narcotic abuse. Adv Nephrol 7: 261–290, 1978.

    Google Scholar 

  177. Citron BP, Halpern M, McCarron M, Lundberg GD, McCormick R, Pincus IJ, Tatter D, Haverback BJ: Necrotizing angiitis associated with drug abuse. N Engl J Med 283: 1003–1011, 1970.

    Article  PubMed  CAS  Google Scholar 

  178. Stein HB, Patterson AC, Offer RC, Atkins CJ, Teufel A, Robinson HS: Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med 92: 24–29, 1980.

    Article  PubMed  CAS  Google Scholar 

  179. Bacon PA, Tribe CR, Mackenzie JC, Verrier-Jones J, Cumming RH, Amer B: Penicillamine nephropathy in rheumatoid arthritis—a clinical, pathological and immunological study. Q J Med 55: 661–684, 1976.

    Google Scholar 

  180. Lachmann PJ: Nephrotic syndrome from penicillamine. Postgrad Med J Suppl 23: 23–27, 1968.

    Google Scholar 

  181. Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson EG: Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature. Am J Kidney Dis 5: 159–163, 1986.

    Google Scholar 

  182. Rehan A, Johnson K: IgM nephropathy associated wtih penicillamine. Am J Nephrol 6: 71–74, 1986.

    Article  PubMed  CAS  Google Scholar 

  183. Katz WA, Blodgett RC, Pietrusko RG: Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 101: 176–179, 1984.

    Article  PubMed  CAS  Google Scholar 

  184. Francis KL, Jenis EH, Jensen GE, Calcagno PL: Gold-associated nephropathy. Arch Pathol Lab Med 108: 234238, 1984.

    Google Scholar 

  185. Blocka KL, Paulus HE, Furst DE: Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacol 11: 133–143, 1986.

    Article  CAS  Google Scholar 

  186. Ueda S, Wakashin M, Wakashin Y, Yoshida H, Lesato K, Mori T, Mori Y, Akikusa B, Okuda K: Experimental gold nephropathy in guinea pigs. Detection of autoantibodies to renal tubular antigens. Kidney Int 29: 539–548, 1986.

    Article  PubMed  CAS  Google Scholar 

  187. Landrigan PJ: Occupational and community exposures to toxic metals: lead, cadmium mercury and arsenic. West J Med 137: 531–539, 1982.

    PubMed  CAS  Google Scholar 

  188. Iesato K, Wakashin M, Wakashin Y, Tojo S: Renal tubular dysfunction in Minimata disease. Ann Intern Med 86: 73 1737, 1977.

    Google Scholar 

  189. Thun MJ, Baker DB, Steenland K, Smith AB, Halperin W, Berl T: Renal toxicity in uranium mill workers. Scand J Work Environ Health 11: 83–90, 1985.

    Article  PubMed  CAS  Google Scholar 

  190. Gerhardt RE, Crecelius EA, Hudson JB: Moonshine-related arsenic poisoning. Arch Intern Med 140: 211–213, 1980.

    Article  PubMed  CAS  Google Scholar 

  191. Finn R, Fennerty RG, Ahmad R: Hydrocarbon exposure and glomerulonephritis. Clin Nephrol 14: 173–175, 1980.

    PubMed  CAS  Google Scholar 

  192. Viau C, Bernard A, Lauwerys R, Buchet JP, Quaeghebeur L, Cornu ME, Phillips SC, Mutti A, Lucertini S, Franchini I: A cross-sectional survey of kidney function in refinery employees. Am J Ind Med 11: 177–187, 1987.

    Article  PubMed  CAS  Google Scholar 

  193. Lauwerys R, Bernard A, Viau C, Buchet JP: Kidney disorders and hematoxicity from organic solvent exposure. Scand J Work Environ Health II (suppl): 83–90, 1985.

    Google Scholar 

  194. Churchill DN, Fine A, Gault MH: Association between hydrocarbon exposure and glomerulonephritis. An appraisal of the evidence. Nephron 33: 169–172, 1983.

    Article  PubMed  CAS  Google Scholar 

  195. Ravnskov U, Forsberg B, Skerfving S: Glomerulonephritis and exposure to organic solvents. Acta Med Scand 205: 575579, 1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Hypertension, and Clinical Pharmacology, Oregon Health Sciences University, Portland, OR, 97201, USA

    William M. Bennett M.D. (Professor of Medicine and Pharmacology)

Authors
  1. William M. Bennett M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Wadi N. Suki M.D. Shaul G. Massry M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bennett, W.M. (1998). Toxic Nephropathy. In: Suki, W.N., Massry, S.G. (eds) Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6632-5_43

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-6632-5_43

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-6634-9

  • Online ISBN: 978-1-4757-6632-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation